Article
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy.
Blood cancer journal - 27 Feb 2023
Moscvin Maria, Liacos Christine Ivy, Chen Tianzeng, Theodorakakou Foteini, Fotiou Despina, Hossain Shahrier, Rowell Sean, Leblebjian Houry, Regan Eileen, Czarnecki Peter, Bagnoli Filippo, Bolli Niccolo', Richardson Paul, Rennke Helmut G, Dimopoulos Meletios A, Kastritis Efstathios, Bianchi Giada
Abstract excerpt
Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leading to microangiopathic hemolytic anemia, platelet consumption, fibrin deposition and small-vessel thrombosis with resultant tissue ischemia. The molecular mechanisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.